Pulmonary pleomorphic carcinoma (PPC) is a rare and aggressive lung malignancy with limited treatment options.
While immune checkpoint inhibitors (ICIs) have shown promise in treating PPC, evidence regarding their efficacy in epidermal growth factor receptor (
